Top-Rated StocksTop-RatedNASDAQ:RVMD Revolution Medicines (RVMD) Stock Price, News & Analysis $41.84 -1.40 (-3.24%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$40.80â–Ľ$43.8050-Day Range$36.92â–Ľ$47.9452-Week Range$15.44â–Ľ$48.61Volume861,530 shsAverage Volume788,312 shsMarket Capitalization$6.99 billionP/E RatioN/ADividend YieldN/APrice Target$52.92 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Revolution Medicines alerts: Email Address Revolution Medicines MarketRank™ Stock AnalysisAnalyst RatingBuy3.08 Rating ScoreUpside/Downside26.5% Upside$52.92 Price TargetShort InterestBearish10.21% of Shares Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment0.86Based on 3 Articles This WeekInsider TradingSelling Shares$2.64 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.47) to ($3.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.05 out of 5 starsMedical Sector167th out of 910 stocksBiological Products, Except Diagnostic Industry19th out of 155 stocks 4.5 Analyst's Opinion Consensus RatingRevolution Medicines has received a consensus rating of Buy. The company's average rating score is 3.08, and is based on 11 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRevolution Medicines has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Revolution Medicines' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.21% of the outstanding shares of Revolution Medicines have been sold short.Short Interest Ratio / Days to CoverRevolution Medicines has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.Change versus previous monthShort interest in Revolution Medicines has recently increased by 4.34%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRevolution Medicines does not currently pay a dividend.Dividend GrowthRevolution Medicines does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRevolution Medicines has received a 74.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Revolution Medicines is -0.81. Previous Next 2.1 News and Social Media Coverage News SentimentRevolution Medicines has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Revolution Medicines this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for RVMD on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Revolution Medicines to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Revolution Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,637,077.00 in company stock.Percentage Held by InsidersOnly 8.00% of the stock of Revolution Medicines is held by insiders.Percentage Held by Institutions94.34% of the stock of Revolution Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Revolution Medicines' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Revolution Medicines are expected to decrease in the coming year, from ($3.47) to ($3.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Revolution Medicines is -11.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Revolution Medicines is -11.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRevolution Medicines has a P/B Ratio of 3.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Revolution Medicines' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. About Revolution Medicines Stock (NASDAQ:RVMD)Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Read More RVMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVMD Stock News HeadlinesSeptember 2, 2024 | americanbankingnews.comAnalysts Set Revolution Medicines, Inc. (NASDAQ:RVMD) Price Target at $52.92August 23, 2024 | uk.finance.yahoo.comargenx SE (ARGX.VI)September 7, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…August 23, 2024 | usatoday.comSemaglutide for weight loss with ReflexMD: Here’s what to knowAugust 11, 2024 | seekingalpha.comRevolution Medicines, Inc. 2024 Q2 - Results - Earnings Call PresentationAugust 8, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Revolution Medicines (RVMD), Personalis (PSNL) and Zimmer Biomet Holdings (ZBH)August 7, 2024 | markets.businessinsider.comRevolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate ProgressAugust 4, 2024 | uk.investing.comRevolution Medicines executive sells over $450k in company stockSeptember 7, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…July 31, 2024 | globenewswire.comRevolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024July 24, 2024 | markets.businessinsider.comOutperform Rating with Raised Price Target for Revolution Medicines Amid Promising Oncology TrialsJuly 8, 2024 | globenewswire.comRevolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024July 8, 2024 | prnewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Revolution Medicines, Inc. (NASDAQ: RVMD)June 8, 2024 | investorplace.comThe 7 Most Undervalued Under-$50 Stocks to Buy in June 2024June 5, 2024 | globenewswire.comRevolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare ConferenceMay 29, 2024 | msn.comCompare with Revolution Medicines Inc (RVMD)May 10, 2024 | finance.yahoo.comRevolution Medicines Reports Q1 2024 Financial Results: Challenges and Strategic Advances in ...May 10, 2024 | finance.yahoo.comRevolution Medicines First Quarter 2024 Earnings: US$0.70 loss per share (vs US$0.72 loss in 1Q 2023)See More Headlines Receive RVMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/07/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RVMD CUSIPN/A CIK1628171 Webwww.revmed.com Phone650-481-6801FaxN/AEmployees250Year FoundedN/APrice Target and Rating Average Stock Price Target$52.92 High Stock Price Target$63.00 Low Stock Price Target$40.00 Potential Upside/Downside+26.5%Consensus RatingBuy Rating Score (0-4)3.08 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($3.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-436,370,000.00 Net MarginsN/A Pretax Margin-70,448.93% Return on Equity-34.57% Return on Assets-30.71% Debt Debt-to-Equity RatioN/A Current Ratio15.43 Quick Ratio15.42 Sales & Book Value Annual Sales$742,000.00 Price / Sales9,303.25 Cash FlowN/A Price / Cash FlowN/A Book Value$11.09 per share Price / Book3.77Miscellaneous Outstanding Shares164,986,000Free Float151,787,000Market Cap$6.90 billion OptionableOptionable Beta1.43 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Mark A. Goldsmith Ph.D. (Age 62)CEO, President & Chairman Comp: $1.12MMr. Jack Anders (Age 47)Chief Financial Officer Comp: $665.28kMs. Margaret A. Horn J.D. (Age 61)Chief Operating Officer Comp: $811.08kDr. Stephen M. Kelsey FRC Path. (Age 63)FRCP, M.D., President of Research & Development Comp: $812.17kMs. Xiaolin Wang (Age 53)Executive Vice President of Development Comp: $633.74kDr. Martin D. Burke M.D.Ph.D., Co-Founder & Chairman of Scientific Advisory BoardDr. Michael A. Fischbach Ph.D. (Age 43)Academic Co-Founder & Member of Scientific Advisory Board Dr. Kevan M. Shokat Ph.D.Academic Co-Founder & Member of Scientific Advisory BoardMr. Walter Reiher Ph.D.Chief Information OfficerMs. Jan Smith Ph.D.Chief Scientific OfficerMore ExecutivesKey CompetitorsMirati TherapeuticsNASDAQ:MRTXKymera TherapeuticsNASDAQ:KYMRModernaNASDAQ:MRNATeva Pharmaceutical IndustriesNYSE:TEVABioNTechNASDAQ:BNTXView All CompetitorsInsiders & InstitutionsTeachers Retirement System of The State of KentuckySold 5,967 shares on 8/26/2024Ownership: 0.019%Point72 Asset Management L.P.Bought 227,922 shares on 8/19/2024Ownership: 0.136%Algert Global LLCBought 33,588 shares on 8/16/2024Ownership: 0.024%Creative PlanningBought 10,667 shares on 8/16/2024Ownership: 0.016%Point72 Asia Singapore Pte. Ltd.Bought 5,966 shares on 8/15/2024Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions RVMD Stock Analysis - Frequently Asked Questions How have RVMD shares performed this year? Revolution Medicines' stock was trading at $28.68 on January 1st, 2024. Since then, RVMD shares have increased by 45.9% and is now trading at $41.84. View the best growth stocks for 2024 here. How were Revolution Medicines' earnings last quarter? Revolution Medicines, Inc. (NASDAQ:RVMD) released its earnings results on Wednesday, August, 7th. The company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.77) by $0.04. The company's revenue for the quarter was down 73.8% on a year-over-year basis. When did Revolution Medicines IPO? Revolution Medicines (RVMD) raised $150 million in an initial public offering on Thursday, February 13th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO. Who are Revolution Medicines' major shareholders? Top institutional investors of Revolution Medicines include Farallon Capital Management LLC (5.84%), Alphabet Inc. (3.22%), Logos Global Management LP (0.73%) and Hood River Capital Management LLC (0.55%). Insiders that own company stock include Rock Ventures Iii LP Third, Thilo Schroeder, Mark A Goldsmith, Stephen Michael Kelsey, Margaret A Horn, Jack Anders, Lorence H Kim, Jeff Cislini, Xiaolin Wang, Sushil Patel and Barbara Weber. View institutional ownership trends. How do I buy shares of Revolution Medicines? Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Revolution Medicines own? Based on aggregate information from My MarketBeat watchlists, some other companies that Revolution Medicines investors own include Alector (ALEC), Editas Medicine (EDIT), Homology Medicines (FIXX), Gossamer Bio (GOSS), Livongo Health (LVGO), Sorrento Therapeutics (SRNE) and Black Diamond Therapeutics (BDTX). This page (NASDAQ:RVMD) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revolution Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RVMD Stock Alerts